CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. RESEARCH METHODOLOGY

1.3.1. Primary research
1.3.2. Secondary research
1.3.3. Analyst tools and models
1.3.4. Market segmentation

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top winning strategies
3.2.2. Top investment pockets
3.2.3. Top impacting factors

3.2.3.1. Surge in application of organ-on-chip devices in the healthcare sector
3.2.3.2. Increase in demand for organ-on-chip in drug screening
3.2.3.3. Rise in demand for lung- & kidney -based organ culture devices
3.2.3.4. High cost of organ-on-chip devices
3.2.3.5. Nascent stage in R&D pertaining to OOCs
3.2.3.6. Increase in research activities on organ-on-chip devices

3.3. PORTERS FIVE FORCES

3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Competitive rivalry

3.4. MARKET PLAYER POSITIONING, 2016
3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Surge in application of organ-on-chip devices in the healthcare sector
3.5.1.2. Increase in demand for organ-on-chips in drug screening
3.5.1.3. Rise in demand for lung- & kidney-based organ culture devices

3.5.2. Restraints

3.5.2.1. High costs of organ-on-chip devices
3.5.2.2. Nascent stage in R&D pertaining to OOCs

3.5.3. Opportunity

3.5.3.1. Increase in research activities on organ-on-chip devices

CHAPTER 4 ORGAN-ON-CHIP MARKET, BY TYPE

4.1. OVERVIEW
4.2. HEART-ON-CHIP

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. HUMAN-ON-CHIP

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. INTESTINE-ON-CHIP

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

4.5. KIDNEY-ON-CHIP

4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast

4.6. LIVER-ON-CHIP

4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast

4.7. LUNG-ON-CHIP

4.7.1. Key market trends
4.7.2. Key growth factors and opportunities
4.7.3. Market size and forecast

CHAPTER 5 ORGAN-ON-CHIP MARKET, BY GEOGRAPHY

5.1. OVERVIEW
5.2. NORTH AMERICA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast, by type
5.2.4. Market size and forecast, by country
5.2.5. U.S.

5.2.5.1. Market size and forecast

5.2.6. Canada

5.2.6.1. Market size and forecast

5.2.7. Mexico

5.2.7.1. Market size and forecast

5.3. EUROPE

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast, by type
5.3.4. Market size and forecast, by country
5.3.5. UK

5.3.5.1. Market size and forecast

5.3.6. Germany

5.3.6.1. Market size and forecast

5.3.7. France

5.3.7.1. Market size and forecast

5.3.8. Rest of Europe

5.3.8.1. Market size and forecast

5.4. ASIA-PACIFIC

5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast, by type
5.4.4. Market size and forecast, by country
5.4.5. China

5.4.5.1. Market size and forecast

5.4.6. Japan

5.4.6.1. Market size and forecast

5.4.7. India

5.4.7.1. Market size and forecast

5.4.8. Australia

5.4.8.1. Market size and forecast

5.4.9. Rest of Asia-Pacific

5.4.9.1. Market size and forecast

5.5. LAMEA

5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast, by type
5.5.4. Market size and forecast, by region
5.5.5. Latin America

5.5.5.1. Market size and forecast

5.5.6. Middle East

5.5.6.1. Market size and forecast

5.5.7. Africa

5.5.7.1. Market size and forecast

CHAPTER 6 COMPANY PROFILES

6.1. AXOSIM TECHNOLOGIES LLC

6.1.1. Company overview
6.1.2. Company snapshot
6.1.3. Operating business segments
6.1.4. Product portfolio

6.2. CN INNOVATIONS HOLDINGS LIMITED (CN BIO INNOVATIONS)

6.2.1. Company overview
6.2.2. Company snapshot
6.2.3. Operating business segments
6.2.4. Product portfolio
6.2.5. Key strategic moves and developments

6.3. EMULATE, INC.

6.3.1. Company overview
6.3.2. Company snapshot
6.3.3. Operating business segments
6.3.4. Product portfolio
6.3.5. Key strategic moves and developments

6.4. ASCENDANCE BIOTECHNOLOGY, INC.

6.4.1. Company overview
6.4.2. Company snapshot
6.4.3. Operating business segments
6.4.4. Product portfolio
6.4.5. Key strategic moves and developments

6.5. HUREL CORPORATION

6.5.1. Company overview
6.5.2. Company snapshot
6.5.3. Operating business segments
6.5.4. Product portfolio
6.5.5. Key strategic moves and developments

6.6. INSPHERO AG

6.6.1. Company overview
6.6.2. Company snapshot
6.6.3. Operating business segments
6.6.4. Product portfolio
6.6.5. Key strategic moves and developments

6.7. MIMETAS B.V.

6.7.1. Company overview
6.7.2. Company snapshot
6.7.3. Operating business segments
6.7.4. Product portfolio
6.7.5. Key strategic moves and developments

6.8. NORTIS INC.

6.8.1. Company overview
6.8.2. Company snapshot
6.8.3. Operating business segments
6.8.4. Product portfolio
6.8.5. Key strategic moves and developments

6.9. ORGANOVO HOLDINGS, INC.

6.9.1. Company overview
6.9.2. Company snapshot
6.9.3. Operating business segments
6.9.4. Product portfolio
6.9.5. Business performance
6.9.6. Key strategic moves and developments

6.10. TARA BIOSYSTEMS, INC.

6.10.1. Company overview
6.10.2. Company snapshot
6.10.3. Operating business segments
6.10.4. Product portfolio
6.10.5. Key strategic moves and developments